AzTrials
AzTrials

Ventricular ThrombusNCT05006677

Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus

An observational study of Ventricular Thrombus, run by China National Center for Cardiovascular Diseases at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To observe the effectiveness and safety of different therapies-non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) or antiplatelet agents and non-antithrombotic therapy - for the treatment of VT. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Ventricular Thrombus
What is being tested?
non-vitamin K antagonist oral anticoagulants (NOACs), vitamin K antagonists (VKAs) and antiplatelet agents
Type of treatment
Pill or oral medicine
How many people
196 participants
Where
1 siteChina
Study dates
4 Aug 2021to 30 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients who had a diagnosis of VT in Fuwai Hospital, National Center of Cardiovascular Diseases in China from July 2010 through March 2022.

Who may be able to join

  • Adults with ventricular thrombus(VT), regardless of sex, basic diseases, occupation or education;
  • The VT should be found newly within 3 months;
  • The observational phase should last until the time that patients who had achieved thrombus resolution. The following up period after the phase ended should continue for at least 3 months.

Who cannot join

  • Individuals received standard antithrombotic therapy within 4 weeks;
  • Individuals received the thrombectomy therapy, ventricular aneurysm resection or heart transplantation within 6 weeks since the VT was found in the first time;
  • Had a long history of VT more than three months.

Trial locations and contacts

1 site in 1 country.

China1 site

  • Qing Yang

    Beijing, 100000

Other trials in China

About this study

To observe the effectiveness and safety of different therapies-non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) or antiplatelet agents and non-antithrombotic therapy - for the treatment of VT.

Being tested
non-vitamin K antagonist oral anticoagulants (NOACs), vitamin K antagonists (VKAs), antiplatelet agents, non-antithrombotic therapy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • non-vitamin K antagonist oral anticoagulants (NOACs)Drug

    Collecting information of patients with VT who received NOACs

  • vitamin K antagonists (VKAs)Drug

    Collecting information of patients with VT who received VKAs

  • antiplatelet agentsDrug

    Collecting information of patients with VT who received antiplatelet agents

  • non-antithrombotic therapyOther

    Collecting information of patients with VT without any antithrombotic therapy

Study groups in NCT05006677
Study groupRoleWhat they receive
non-vitamin K antagonist oral anticoagulants (NOACs)Not described
Receives: Drug: non-vitamin K antagonist oral anticoagulants (NOACs)
vitamin K antagonists (VKAs)Not described
Receives: Drug: vitamin K antagonists (VKAs)
antiplatelet agentsNot described
Receives: Drug: antiplatelet agents
non-antithrombotic therapyNot described
Receives: Other: non-antithrombotic therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Thrombus resolution in 12 weeks follow-up

    Thrombus resolution in 12 weeks follow-up

    Measured: 12 weeks

Secondary outcomes (6)

  1. Thrombus resolution in 6 weeks follow-up

    Thrombus resolution in 6 weeks follow-up

    Measured: 6 weeks

  2. Thrombus resolution in 6 months follow-up

    Thrombus resolution in 6 months follow-up

    Measured: 6 months

  3. Thrombus resolution in 12 months follow-up

    Thrombus resolution in 12 months follow-up

    Measured: 12 months

  4. Thromboembolism events

    Thromboembolism events

    Measured: 12 months

  5. Bleeding

    Bleeding

    Measured: 12 months

  6. All-cause death

    All-cause death

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Aug 2021
  2. Study start4 Aug 2021
  3. Primary completion30 Oct 2023
  4. Study completion30 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Retrospective
Enrolment
196 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05006677
Sponsor's protocol ID
2021-TR
Status last verified
Mar 2023
First submitted
8 Aug 2021
Last updated
27 Oct 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Gianstefani S, Douiri A, Delithanasis I, Rogers T, Sen A, Kalra S, Charangwa L, Reiken J, Monaghan M, MacCarthy P. Incidence and predictors of early left ventricular thrombus after ST-elevation myocardial infarction in the contemporary era of primary percutaneous coronary intervention. Am J Cardiol. 2014 Apr 1;113(7):1111-6. doi: 10.1016/j.amjcard.2013.12.015. Epub 2014 Jan 14.

    PubMed 24485697

  • Turpie AG, Robinson JG, Doyle DJ, Mulji AS, Mishkel GJ, Sealey BJ, Cairns JA, Skingley L, Hirsh J, Gent M. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989 Feb 9;320(6):352-7. doi: 10.1056/NEJM198902093200604.

    PubMed 2643772

  • Abdelnaby M, Almaghraby A, Abdelkarim O, Saleh Y, Hammad B, Badran H. The role of rivaroxaban in left ventricular thrombi. Anatol J Cardiol. 2019 Jan;21(1):47-50. doi: 10.14744/AnatolJCardiol.2018.48313. No abstract available.

    PubMed 30587707

  • Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC); Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215. Epub 2012 Aug 24. No abstract available.

    PubMed 22922416

  • He J, Ge H, Dong JX, Zhang W, Kong LC, Qiao ZQ, Zheng Y, Ding S, Wan F, Shen L, Wang W, Gu ZC, Yang F, Li Z, Pu J. Rationale and design of a prospective multi-center randomized trial of EARLY treatment by rivaroxaban versus warfarin in ST-segment elevation MYOcardial infarction with Left Ventricular Thrombus (EARLY-MYO-LVT trial). Ann Transl Med. 2020 Mar;8(6):392. doi: 10.21037/atm.2020.02.117.

    PubMed 32355836

  • Guddeti RR, Anwar M, Walters RW, Apala D, Pajjuru V, Kousa O, Gujjula NR, Alla VM. Treatment of Left Ventricular Thrombus With Direct Oral Anticoagulants: A Retrospective Observational Study. Am J Med. 2020 Dec;133(12):1488-1491. doi: 10.1016/j.amjmed.2020.05.025. Epub 2020 Jun 27.

    PubMed 32598904

  • Cai Y, Yang Q, Quan X, Lang X, Yu L, Yang Y, Zhu J, Liang Y. Impact of left ventricular ejection fraction on left ventricular thrombus resolution. J Cardiothorac Surg. 2026 Apr 21;21(1):543. doi: 10.1186/s13019-026-04106-9.

    PubMed 42015174

  • Yang Q, Liang Y, Quan X, Lang X, Gao D. Characteristics of Novel Anticoagulants versus Vitamin K Antagonists in the Ventricular Mural Thrombus. Rev Cardiovasc Med. 2023 Mar 2;24(3):74. doi: 10.31083/j.rcm2403074. eCollection 2023 Mar.

    PubMed 39077494

  • Yang Q, Quan X, Lang X, Liang Y. Predicting Thromboembolism in Hospitalized Patients with Ventricular Thrombus. Rev Cardiovasc Med. 2022 Nov 30;23(12):390. doi: 10.31083/j.rcm2312390. eCollection 2022 Dec.

    PubMed 39076670

  • Yang Q, Lang X, Quan X, Gong Z, Liang Y. Different Oral Antithrombotic Therapy for the Treatment of Ventricular Thrombus: An Observational Study from 2010 to 2019. Int J Clin Pract. 2022 Feb 24;2022:7400860. doi: 10.1155/2022/7400860. eCollection 2022.

    PubMed 35685496

Questions about this trial

What is this clinical trial studying?

An observational study of Ventricular Thrombus, run by China National Center for Cardiovascular Diseases at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Thrombus resolution in 12 weeks follow-up (time frame: 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05006677, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in